Everest Medicines Limited (HKG:1952)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
46.40
-3.30 (-6.64%)
Apr 24, 2025, 4:08 PM HKT
94.96%
Market Cap 15.05B
Revenue (ttm) 752.03M
Net Income (ttm) -1.11B
Shares Out 324.43M
EPS (ttm) -3.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,133,890
Average Volume 6,094,126
Open 50.20
Previous Close 49.70
Day's Range 45.40 - 51.15
52-Week Range 18.18 - 69.00
Beta 1.70
RSI 42.91
Earnings Date Aug 25, 2025

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 665
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1952
Full Company Profile

Financial Performance

In 2024, Everest Medicines's revenue was 706.68 million, an increase of 461.16% compared to the previous year's 125.93 million. Losses were -1.04 billion, 23.3% more than in 2023.

Financial numbers in CNY Financial Statements

News

AI-powered Cancer Vaccine In The Works

The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine's EVM14 cancer vaccin...

4 weeks ago - Benzinga

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Enrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data to first half 2025 PALIZADE Phase 2b clinical trial of ...

9 months ago - Benzinga